The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection
Open accessAbstract
As the novel Coronavirus Disease 2019 (COVID-19) outbreak expands, identification of predictive factors for severe infection is essential to enable risk stratification, optimize reallocation of hospital resource, and guide public health recommendations and interventions. Chronic Kidney disease (CKD) is associated with an increased risk of both inpatient and outpatient pneumonia [1]. Moreover, the pneumoniarelated mortality rate in CKD patients seems to be 14–16 times higher than in the general population [2]. In this article, we aim to explore the potential association between CKD and severity of COVID-19 infection. A search of electronic databases, based on Medline (PubMed interface), Scopus and Web of Science, was carried out with the keywords “chronic renal disease” OR “chronic kidney disease” OR “clinical characteristics” AND “coronavirus 2019” OR “COVID-19” OR “2019-nCoV” OR “SARS-CoV-2”, between 2019 and present time (i.e., March 9, 2020) with no language restrictions applied. The title, abstract and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of CKD in COVID-19 patients with clinically validated definition of “severe disease” were included in this metaanalysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles. A meta-analysis was performed on retrievable data, including the estimation of the odds ratio (OR) and its 95% confidence interval (95% CI) in patients with or without severe forms of COVID-19. The statistical analysis was performed with MetaXL, software Version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia). The study was carried out in accordance with the Declaration of Helsinki and with the term of local legislation. Overall, 84 articles could be originally detected based on our electronic and reference search which, after screening by title, abstract and full text, 80 were excluded as not specifically related to COVID-19 (n = 25), were review articles (n = 7), did not provide relevant data (n = 28), were editorials (n = 10), did not include information on severity and/or comorbidities (n = 8), compared patients by mortality but not by severity (n = 1), or compared mild to critical cases (n = 1). Therefore, a final number of four studies could be included in our meta-analysis, including 1389 COVID-19 patients, among which 273 (19.7%) were classified as having severe disease [3–6]. The essential characteristics of included studies are summarized in Table 1, whilst the individual and pooled ORs for CKD predicting severe COVID-19 is shown in Fig. 1. No study individually found CKD as significant clinical predictor of severe COVID-19. However, when data of individual studies were pooled, a significant association of CKD with severe COVID-19 was observed, with no relevant heterogeneity [OR 3.03 (95% CI 1.09–8.47), I2 = 0.0%, Cochran’s Q, p = 0.84]. Based on a contrite meta-analysis of early and preliminarily available data, CKD seems to be associated with enhanced risk of severe COVID-19 infection. Patients with CKD should hence be advised to take extra precaution to minimize risk exposure to the virus. Physicians should also be engaged in close monitoring of CKD patients with suspected COVID-19, for timely detecting signs of disease progression. Finally, the presence of CKD shall be regarded as an important factor in future risk stratification models for COVID-19. * Brandon Michael Henry Brandon.henry@cchmc.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004
Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,031
Pulmonary Infectious Mortality Among Patients With End-Stage Renal Disease
Sarnak, M. J., & Jaber, B. L. (2001) · Chest · doi:10.1378/chest.120.6.1883 · Cited by 249
Cited by
Beyerstedt, S., Casaro, E. B., & Rangel, É. B. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04138-6 · Cited by 897
The role of biomarkers in diagnosis of COVID-19 – A systematic review
Kermali, M., Khalsa, R. K., Pillai, K., Ismail, Z., & Harky, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117788 · Cited by 687
Izcovich, A., Ragusa, M. A., Tortosa, F., Lavena Marzio, M. A., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241955 · Cited by 660
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 592
Bellan, M., Soddu, D., Balbo, P. E., Baricich, A., Zeppegno, P., Avanzi, G. C., Baldon, G., Bartolomei, G., Battaglia, M., Battistini, S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36142 · Cited by 474
Jain, V., & Yuan, J.-M. (2020) · International Journal of Public Health · doi:10.1007/s00038-020-01390-7 · Cited by 465
Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis
Lippi, G., Wong, J., & Henry, B. M. (2020) · Polish Archives of Internal Medicine · doi:10.20452/pamw.15272 · Cited by 421
Self-citationHarrison, S. L., Fazio-Eynullayeva, E., Lane, D. A., Underhill, P., & Lip, G. Y. H. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003321 · Cited by 414
Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G., & Schultz-Cherry, S. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00542-7 · Cited by 402
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
ERA-EDTA Council, Ortiz, A., Cozzolino, M., Fliser, D., Fouque, D., Goumenos, D., Massy, Z. A., Rosenkranz, A. R., Rychlık, I., Soler, M. J., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa314 · Cited by 372
Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide
Sanchis-Gomar, F., Lavie, C. J., Mehra, M. R., Henry, B. M., & Lippi, G. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.05.006 · Cited by 370
Self-citationCovid‐19 and kidney injury: Pathophysiology and molecular mechanisms
Ahmadian, E., Hosseiniyan Khatibi, S. M., Razi Soofiyani, S., Abediazar, S., Shoja, M. M., Ardalan, M., & Zununi Vahed, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2176 · Cited by 366
A model of disparities: risk factors associated with COVID-19 infection
Rozenfeld, Y., Beam, J., Maier, H., Haggerson, W., Boudreau, K., Carlson, J., & Medows, R. (2020) · International Journal for Equity in Health · doi:10.1186/s12939-020-01242-z · Cited by 358
Bodaghi, A., Fattahi, N., & Ramazani, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13323 · Cited by 336
RetractedA metabolic handbook for the COVID-19 pandemic
Ayres, J. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0237-2 · Cited by 292
Risk Factors for Mortality in Patients with COVID-19 in New York City
Mikami, T., Miyashita, H., Yamada, T., Harrington, M., Steinberg, D., Dunn, A., & Siau, E. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05983-z · Cited by 284
Flaherty, G. T., Hession, P., Liew, C. H., Lim, B. C. W., Leong, T. K., Lim, V., & Sulaiman, L. H. (2020) · Tropical Diseases, Travel Medicine and Vaccines · doi:10.1186/s40794-020-00118-y · Cited by 127
Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations
Helms, L., Marchiano, S., Stanaway, I. B., Hsiang, T.-Y., Juliar, B. A., Saini, S., Zhao, Y. T., Khanna, A., Menon, R., Alakwaa, F., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.154882 · Cited by 47
Rinderknecht, M. D., & Klopfenstein, Y. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00482-9 · Cited by 23
COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?
Pallarés Carratalá, V., Górriz-Zambrano, C., Morillas Ariño, C., Llisterri Caro, J. L., & Gorriz, J. L. (2020) · Medicina de Familia. SEMERGEN · doi:10.1016/j.semerg.2020.05.005 · Cited by 21
Metadata
- Authors
- Henry, B. M., & Lippi, G.
- Venue
- International Urology and Nephrology
- Published
- 2020-03-28
- Volume
- 52
- Issue
- 6
- Pages
- 1193-1194
- ISSN
- 0301-1623 (ISSN-L)
- 1573-2584
- OpenAlex
- W3014090262
- Cited by
- 547
- References
- 6
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.